Thus, the combination of PIN1- and CDK4-inhibitors achieves synergistic anti-tumor activity against Rb-proficient or -deficient TNBC in immune-compromised or -competent mice, with an excellent safety profile, making it a strong candidate for clinical development. The gene discussed is PIN1; the disease is neoplasm.